186 related articles for article (PubMed ID: 34995529)
1. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last.
Le Berre C; Ricciuto A; Peyrin-Biroulet L; Turner D
Gastroenterology; 2022 Apr; 162(5):1424-1438. PubMed ID: 34995529
[TBL] [Abstract][Full Text] [Related]
2. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Turner D; Ricciuto A; Lewis A; D'Amico F; Dhaliwal J; Griffiths AM; Bettenworth D; Sandborn WJ; Sands BE; Reinisch W; Schölmerich J; Bemelman W; Danese S; Mary JY; Rubin D; Colombel JF; Peyrin-Biroulet L; Dotan I; Abreu MT; Dignass A;
Gastroenterology; 2021 Apr; 160(5):1570-1583. PubMed ID: 33359090
[TBL] [Abstract][Full Text] [Related]
3. [Evolving Therapeutic Strategies in the Inflammatory Bowel Disease].
Na SY; Moon W
Korean J Gastroenterol; 2018 Feb; 71(2):61-68. PubMed ID: 29471602
[TBL] [Abstract][Full Text] [Related]
4. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?
Dal Buono A; Roda G; Argollo M; Zacharopoulou E; Peyrin-Biroulet L; Danese S
Expert Rev Gastroenterol Hepatol; 2020 Sep; 14(9):807-817. PubMed ID: 32762582
[TBL] [Abstract][Full Text] [Related]
5. Treat to target in Crohn's disease: A practical guide for clinicians.
Srinivasan AR
World J Gastroenterol; 2024 Jan; 30(1):50-69. PubMed ID: 38293329
[TBL] [Abstract][Full Text] [Related]
6. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD.
Le Berre C; Peyrin-Biroulet L;
Gastroenterology; 2021 Apr; 160(5):1452-1460.e21. PubMed ID: 33421515
[TBL] [Abstract][Full Text] [Related]
7. [New therapeutic goals in inflammatory bowel diseases].
Vuitton L; Peyrin-Biroulet L
Rev Prat; 2014 Nov; 64(9):1232-6. PubMed ID: 25638861
[TBL] [Abstract][Full Text] [Related]
8. Treat to target in inflammatory bowel disease: a survey of treatment strategies amongst Portuguese doctors.
Bernardo S; Fernandes SR; Araújo-Correia L
Rev Esp Enferm Dig; 2019 Aug; 111(8):593-597. PubMed ID: 31190548
[TBL] [Abstract][Full Text] [Related]
9. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Peyrin-Biroulet L; Sandborn W; Sands BE; Reinisch W; Bemelman W; Bryant RV; D'Haens G; Dotan I; Dubinsky M; Feagan B; Fiorino G; Gearry R; Krishnareddy S; Lakatos PL; Loftus EV; Marteau P; Munkholm P; Murdoch TB; Ordás I; Panaccione R; Riddell RH; Ruel J; Rubin DT; Samaan M; Siegel CA; Silverberg MS; Stoker J; Schreiber S; Travis S; Van Assche G; Danese S; Panes J; Bouguen G; O'Donnell S; Pariente B; Winer S; Hanauer S; Colombel JF
Am J Gastroenterol; 2015 Sep; 110(9):1324-38. PubMed ID: 26303131
[TBL] [Abstract][Full Text] [Related]
10. Deep remission in inflammatory bowel disease: looking beyond symptoms.
Zallot C; Peyrin-Biroulet L
Curr Gastroenterol Rep; 2013 Mar; 15(3):315. PubMed ID: 23354742
[TBL] [Abstract][Full Text] [Related]
11. Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges.
Dignass A; Rath S; Kleindienst T; Stallmach A
Aliment Pharmacol Ther; 2023 Sep; 58(5):492-502. PubMed ID: 37382397
[TBL] [Abstract][Full Text] [Related]
12. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative.
Bryant RV; Winer S; Travis SP; Riddell RH
J Crohns Colitis; 2014 Dec; 8(12):1582-97. PubMed ID: 25267173
[TBL] [Abstract][Full Text] [Related]
13. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.
Vuitton L; Peyrin-Biroulet L; Colombel JF; Pariente B; Pineton de Chambrun G; Walsh AJ; Panes J; Travis SP; Mary JY; Marteau P
Aliment Pharmacol Ther; 2017 Mar; 45(6):801-813. PubMed ID: 28112419
[TBL] [Abstract][Full Text] [Related]
14. Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?
Agrawal M; Colombel JF
Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):421-436. PubMed ID: 31078245
[TBL] [Abstract][Full Text] [Related]
15. Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis.
Núñez F P; Krugliak Cleveland N; Quera R; Rubin DT
World J Gastroenterol; 2021 May; 27(20):2521-2530. PubMed ID: 34092973
[TBL] [Abstract][Full Text] [Related]
16. The Role of Histology in Determining Disease Activity, Treatment, and Prognosis: Are We There yet?
Salem MS; Melmed GY
Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):437-446. PubMed ID: 31078246
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.
Colombel JF; D'haens G; Lee WJ; Petersson J; Panaccione R
J Crohns Colitis; 2020 Feb; 14(2):254-266. PubMed ID: 31403666
[TBL] [Abstract][Full Text] [Related]
18. Current therapeutic approaches in inflammatory bowel disease.
Sohrabpour AA; Malekzadeh R; Keshavarzian A
Curr Pharm Des; 2010; 16(33):3668-83. PubMed ID: 21128898
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory bowel disease. Part II: Clinical and therapeutic aspects.
Kirsner JB
Dis Mon; 1991 Nov; 37(11):669-746. PubMed ID: 1935537
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory bowel disease. Part I: Nature and pathogenesis.
Kirsner JB
Dis Mon; 1991 Oct; 37(10):605-66. PubMed ID: 1893828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
